Peter J. Rosen

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Daniel D. Von Hoff, Joseph J. Stephenson, Peter J. Rosen et al. · Journal of Clinical Oncology · 2010 · 628 citations

Cancer Management, Oligonucleotide Microarray, Pathology +22

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman et al. · Blood · 2012 · 254 citations · Full text

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

Howard I. Scher, Xiaoyu Jia, Kim Chi et al. · Journal of Clinical Oncology · 2011 · 247 citations · Full text

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Mitesh J. Borad, Shantan Reddy, Nathan Bahary et al. · Journal of Clinical Oncology · 2014 · 186 citations · Full text

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi et al. · Cancer · 2013 · 174 citations · Full text